Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PET and EBV DNA-directed Therapy for Localized Nasal Extranodal NK/T Cell Lymphoma

NCT06069830 is registered in ClinicalTrials.gov with Ruijin Hospital as lead sponsor.

NCT NCT06069830
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06069830 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PET and EBV DNA-directed Therapy for Localized Nasal Extranodal NK/T Cell Lymphoma
Lead sponsor
Ruijin Hospital
Phase
Not applicable
Overall status
Recruiting
Start date
December 6, 2023
Completion date
October 31, 2026
Enrollment
89 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

nk-t-cell lymphoma, extranodal